This retrospective analysis correlates ADC values with Gleason scores in prostate cancer, indicating potential for improved diagnostics.
Background: Accurate characterization of prostate cancer (PCa) aggressiveness remains a clinical challenge. While multiparametric MRI (mpMRI) and Prostate Imaging Reporting and Data System (PI-RADS) scoring are widely used, their qualitative nature introduces inter-reader variability. Apparent diffusion coefficient (ADC) values derived from diffusion-weighted imaging (DWI) may provide a more objective biomarker of tumor severity. Methods: We retrospectively analyzed 181 lesions from 101 patients with biopsy-proven PCa (2019-2025). The lowest or minimum ADC (ADCmin) value (µm2/s) was recorded for each lesion and correlated with Gleason scores: low-risk (3+3), intermediate-favorable (3+4), intermediate-unfavorable (4+3), and high-risk (≥4+4). Statistical analysis was performed using Welch’s analysis of variance (ANOVA) with Games-Howell post hoc testing. Results: Mean ADC values showed a progressive decline with increasing Gleason category: 3+3 = 456.5 ± 191 µm2/s; 3+4 = 382.0 ± 188 µm2/s; 4+3 = 296.2 ± 130 µm2/s; ≥4+4 = 222.6 ± 134 µm2/s. Interquartile ranges (IQRs) similarly decreased across categories. Welch’s ANOVA demonstrated significant overall group differences (F(3, 84.78) = 18.95, p < 0.001). Games-Howell post hoc tests revealed significantly lower ADC values in 4+3 and ≥4+4 compared with 3+3 (p < 0.001) and in ≥4+4 compared with 3+4 (p < 0.001). Conclusion: MRI-derived ADC values inversely correlate with Gleason scores, suggesting their potential as a non-invasive biomarker for PCa aggressiveness. Incorporating ADC values into clinical workflows may enhance biopsy targeting, risk stratification, and treatment planning.
No takes yet. Share an insight, caveat, or question.
Bird et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: